Sign In
Last checked at 
24 Dec 2024 11:25
Shield Therapeutics plc
("Shield" or the "Company" or the "Group")
Result of General Meeting and Total Voting Rights
Shareholder approval for $10 million Subscription and Panel Waiver
London, UK, 24 December 2024: Shield Therapeutics plc (LSE: STX) is pleased to announce that, at the General Meeting held earlier today, all Resolutions (including the Waiver Resolution) as set out in the Notice of General Meeting contained in the Circular published on 6 December 2024, were duly passed. Accordingly, subject to Admission, the Company has raised gross proceeds of $10 million pursuant to the Subscription and in addition the Panel Waiver has been approved. Further, as announced on 23 December 2024, the RetailBook Offer has also raised £96,715.83 (before expenses) for the Company.
Admission and Total Voting Rights
Following the General Meeting held earlier today, the Company will issue a total of 259,634,117 new Ordinary Shares ("New Ordinary Shares") made up of 256,410,256 Subscription Shares and 3,223,861 RetailBook Offer Shares.
Application has been made to the London Stock Exchange for admission of the New Ordinary Shares to trading on AIM. It is expected that Admission will become effective and dealings in the New Ordinary Shares will commence on AIM at 8.00 a.m. on 30 December 2024. The New Ordinary Shares will rank pari passu in all respects with the Existing Ordinary Shares.
Following Admission, the total number of Ordinary Shares in the capital of the Company in issue will be 1,041,690,484 with equal voting rights. No shares are held in treasury.
This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company's share capital pursuant to (i) the Company's Articles, (ii) the Financial Conduct Authority's Disclosure Guidance and Transparency Rules and/or (iii) the AIM Rules for Companies issued by the London Stock Exchange plc as amended from time to time.
Results of the meeting
Details of the results of the voting, by way of a poll vote, at the General Meeting are set out below. Resolutions 1 to 2 are ordinary resolutions and Resolution 3 is a special resolution.
Resolution | Votes For | Votes For (as % of votes cast) | Votes Against | Votes Against (as % of votes cast)
| Vote Withheld |
1* | 102,899,680 | 98.07% | 2,024,299 | 1.93% | 323,522,105 |
2 | 426,064,758 | 99.51% | 2,108,199 | 0.49% | 273,127 |
3 | 426,044,147 | 99.52% | 2,044,320 | 0.48% | 357,617 |
*Resolution 1 was taken on a poll of Independent Shareholders (as defined in the Circular) in accordance with the requirements of the Takeover Code.
Resultant holding of AOP and members of its Concert Party
The following table sets out the shareholdings of AOP and each member of its concert party following Admission:
Shareholder | Number of Ordinary Shares held following Admission
| Percentage of the Enlarged Share Capital following Admission |
AOP | 568,007,521 | 54.53 |
Dr. Christian Schweiger | 11,651,713 | 1.12 |
Dr. Günther Krumpl | 4,000,000 | 0.38 |
Michael Steiger | 625,000 | 0.06 |
Total | 584,284,234 | 56.09 |
Capitalised terms used but not otherwise defined in this announcement shall have the meanings ascribed to such terms in the Company's announcement at 11.30 a.m. on 6 December 2024, unless the context requires otherwise.
For further information please contact:
Shield Therapeutics plc | www.shieldtherapeutics.com |
Anders Lundstrom, CEO Santosh Shanbhag, CFO | +44 (0) 191 511 8500 |
Nominated Adviser and Joint Broker | |
Peel Hunt LLP | |
James Steel / Patrick Birkholm | +44 (0)20 7418 8900 |
Joint Broker Cavendish Ltd Geoff Nash / Rory Sale / Nigel Birks / Harriet Ward |
+44 (0)20 7220 0500 |
Financial PR & IR Advisor | |
Walbrook PR | |
Alice Woodings / Lianne Applegarth | +44 (0)20 7933 8780 or shield@walbrookpr.com |
About Iron Deficiency and ACCRUFeR®/FeRACCRU®
Clinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR® has the potential to meet an important unmet medical need for both physicians and patients.
ACCRUFeR®/FeRACCRU® (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA. The drug has a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR®/FeRACCRU®, including the product label, can be found at: www.accrufer.com and www.feraccru.com.
About Shield Therapeutics plc
Shield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR®/FeRACCRU® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched ACCRUFeR® in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies. FeRACCRU® is commercialized in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of ACCRUFeR®/ FeRACCRU® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, and with KYE Pharmaceuticals Inc. for Canada.
ACCRUFeR®/FeRACCRU® has patent coverage until the mid-2030s.
ACCRUFeR®/FeRACCRU® are registered trademarks of Shield Therapeutics.
Follow the stocks
